Synthesis and evaluation of a novel inhibitor for the α5‐GABA <sub>A</sub> receptor in the treatment of peripheral neuralgia: Evidence from MD simulation and in vivo studies
SR-419 is a peripherally acting GABRA5 inhibitor with potent analgesic efficacy and a favourable safety profile. Its target-specific mechanism suggests that it is a promising candidate for treating PNP and avoiding central side effects.
Authors
- Dehua Lu (ORCID: https://orcid.org/0000-0003-0399-7769)
- Guo‐Gang Xing (ORCID: https://orcid.org/0000-0001-5670-4857)
- Zhenming Liu (ORCID: https://orcid.org/0000-0002-8993-4015)
- Jiaxu Zhou (ORCID: https://orcid.org/0000-0002-7720-0700)
- Yiqiao Liu
- Weiping Lyu
- Cheng Shi (ORCID: https://orcid.org/0000-0003-0329-4369)
- Xiangyu Zhang (ORCID: https://orcid.org/0000-0002-4858-5429)
- Xia Li (ORCID: https://orcid.org/0009-0007-0823-4716)
- Yanming Chen (ORCID: https://orcid.org/0000-0001-6902-5327)
- Jie Cai (ORCID: https://orcid.org/0000-0002-6473-0585)
- Yue Tian (ORCID: https://orcid.org/0000-0003-1719-0894)
Institutions
- China Pharmaceutical University (CN)
- Peking University (CN)
- Nanjing University (CN)
Publication Details
- Journal
- British Journal of Pharmacology
- Published
- 2025-08-09
- DOI
- https://doi.org/10.1111/bph.70150
- Primary Topic
- Pain Mechanisms and Treatments
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- National Natural Science Foundation of China
- China Postdoctoral Science Foundation
- Nanjing University
- State Key Laboratory of Pharmaceutical Biotechnology
- Beijing Municipal Natural Science Foundation